Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Tumor hyperinsulinism
Economic impact of diagnostic testing
3 evidence topics · 3 sources
Inpatient 72-hour fast for insulinoma: duration and cost (quality improvement report)
“test for detecting insulinoma but imposes significant burdens on patients and expends hospital resources.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The original protocol had an average fast duration of 57.6 hours (median 72 hours, IQR [49,72]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This reduced cumulative inpatient fasting by 376.5 hours and reduced medical costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adding a BHB >2.7 mmol/L stopping criterion reduced inpatient hospitalization time, medical costs, and patient burden without compromising insulinoma detection.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prolonged fasting test when hypoglycemia does not occur spontaneously (insulinoma)
“If hypoglycemia does not occur spontaneously, a 72-hour prolonged fasting test should be performed and blood should be drawn for measurements of insulin, and pro-insulin, or C-peptide measurements if hypoglycemia occurs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Availability of big IGF-II measurement for NICTH diagnosis
“To our knowledge, there is no commercially available assay for big IGF-II, and measurement of high molecular weight precursor forms of IGF-II must be done in a research laboratory setting at this time.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nevertheless, a widely available assay would assist all practitioners, especially those without access to a research laboratory.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cost of diagnostic testing for tumor hyperinsulinism
No evidence found.